Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

NCT02222155 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

ANCA-associated Vasculitis

Interventions

DRUG: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
DRUG: CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
OTHER: Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids

Sponsor

Amgen